AP303 / Alebund - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Alebund Pharmaceuticals

New P1 trial • Diabetic Nephropathy • Nephrology • Renal Disease

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Alebund Pharmaceuticals | Not yet recruiting ➔ Completed

Trial completion

Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PRNewswire) - "Alebund Pharmaceuticals...announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AP303 for the treatment of autosomal dominant polycystic kidney disease (ADPKD)....This Orphan Drug Designation reflects the need for more new treatment options and the potential for AP303 to address the pressing needs of people living with ADPKD."

Orphan drug • Autosomal Dominant Polycystic Kidney Disease • Polycystic Kidney Disease • Renal Disease

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Alebund Pharmaceuticals

New P1 trial

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects (clinicaltrials.gov) - P1 | N=62 | Completed | Sponsor: Alebund Pty Ltd | Recruiting ➔ Completed

Trial completion

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects (clinicaltrials.gov) - P1 | N=62 | Recruiting | Sponsor: Alebund Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects (clinicaltrials.gov) - P1 | N=62 | Not yet recruiting | Sponsor: Alebund Pty Ltd

New P1 trial